The JAK1 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that introduces a targeted disruption of the JAK1 gene in the 786-O human renal cell carcinoma line. This loss-of-function model provides a heterogeneous cell pool, avoiding clonal selection biases, and enables robust investigation of JAK1-dependent signaling networks. It is an ideal tool for functional genomics, cancer biology, and cytokine signaling studies.
The 786-O cell line is derived from a human clear cell renal adenocarcinoma and displays an adherent epithelial morphology. As a well-characterized kidney cancer model, 786-O retains key oncogenic pathways, including constitutive and cytokine-inducible JAK-STAT signaling. Its reproducible growth characteristics and defined genetic background make it a reliable platform for dissecting signal transduction mechanisms relevant to renal cell carcinoma.
JAK1 encodes a non-receptor tyrosine kinase that associates with cytokine receptor chains such as IL-6R and IFNGR1. Upon ligand binding by IL-6 or IFN-gamma, JAK1 is activated and phosphorylates STAT1, STAT3, and STAT5. These STATs dimerize, enter the nucleus, and regulate genes controlling proliferation and immune responses. Negative regulators include SOCS1 and PIAS, and JAK1 often partners with JAK2. Thus, JAK1 functions as a central signaling hub connecting extracellular cytokine cues to transcriptional programs.
In 786-O renal cell carcinoma, JAK1 signaling promotes tumor growth and immune evasion. Disrupting JAK1 removes a key mediator of cytokine-driven oncogenic pathways, allowing dissection of its role in cancer biology. This model is valuable for studying responses to inflammatory cytokines and assessing JAK1 dependency in processes like proliferation and apoptosis. It also illuminates autocrine/paracrine JAK-STAT activation mechanisms in clear cell renal carcinoma.
Applications include cytokine signal transduction analysis, oncogenic signaling studies, and therapeutic target validation. Assays such as phospho-JAK1 western blotting, RT-qPCR of STAT targets, and flow cytometry for STAT phosphorylation are routinely used. Functional assays like proliferation and apoptosis measurements complement these analyses. For additional details, please contact Ascent Research.
